DIRS.INFO The most relevant business & tech news

☆ Beware these stocks that rely on government spending if Musk’s DOGE threatens budgets
▼ + stars: | 2024-11-19 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Given this overhang, Morgan Stanley's sales team created a whole basket of stocks that have a large exposure to government spending. gov Relatively high revenue from government, as estimated by Morgan Stanley Notably, the list mostly excludes defense contractors, as Morgan Stanley expects them to be more insulated from budget cuts. Stocks in the basket include these 10: Moderna and Pfizer are two companies that made the basket. While the average analyst polled by LSEG has a hold rating, the average price target implies the stock will nearly double over the next year. MRNA PFE YTD mountain Moderna and Pfizer, year to date Research and consulting firm Gartner was also included in the Morgan Stanley basket.

Persons: Donald Trump's, Trump, Elon, Vivek Ramaswamy, it's, Morgan, Morgan Stanley, Trump's, Robert F, Kennedy Jr, LSEG, Gartner Organizations: Tesla, Roivant Sciences, Department of Government Efficiency, Intuit, Washington Post, Internal Revenue, gov, Moderna, Pfizer, Human Services, Research, Gartner Locations: Stamford , Connecticut

☆ How we're thinking about Eli Lilly after Trump picked obesity-drug critic RFK Jr. to run HHS
▼ + stars: | 2024-11-15 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +7 min

Shares of obesity drugmaker Eli Lilly fell more than 4% on Friday, extending a roughly 3% slide in Thursday's session. Ozempic is the posterchild of the fast-growing GLP-1 class, in which Novo Nordisk and Eli Lilly are currently the two dominant players. Bottom line Eli Lilly has been our favorite drug stock for years thanks to its stellar pipeline led by GLP-1s. But, at this point, Kennedy's nomination requires us to be more cautious on Eli Lilly in the near term. Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain.

Persons: Eli Lilly, Donald Trump, Robert F, Kennedy Jr, Kentucky Sen, Rand Paul, Kennedy, Trump, Eli Lilly's, John F, Kennedy —, LLY, Eli Lilly's GLP, Jim Cramer, David Ricks, Lilly, It's, Jim, it's, Jim Cramer's, Cristina Arias Organizations: Republican, Department of Health, Human Services, HHS, and Drug Administration, Centers for Disease Control, Medicare, Medicaid, Senate, Democratic, GOP, Media, Novo Nordisk, Moderna, Pfizer, Deutsche Bank, GSK, White, CDC, Street Journal, GLP, Big Pharma, FDA, tirzepatide, CNBC, Company, Pharmaceutical Locations: Washington, Kentucky, Danish, U.S, Alcobendas, Madrid, Spain

☆ Stocks making the biggest moves midday: Palantir, Moderna, Ulta Beauty, Alibaba and more
▼ + stars: | 2024-11-15 | by ( Pia Singh | In | ) www.cnbc.com time to read: +3 min

Global pharma stocks — Shares of several vaccine makers declined after President-elect Donald Trump selected prominent vaccine skeptic Robert F. Kennedy Jr. as health secretary on Thursday. Shares of Moderna and Pfizer slipped nearly 9% and 5%, respectively. Ulta slipped nearly 3% after Berkshire Hathaway revealed in a regulatory filing that it had sold around 97% of its shares, nearly dissolving its position in the beauty retailer. Berkshire had just bought the stock in the second quarter, making Ulta a relatively new bet. However, the company beat expectations on both lines in the fourth fiscal quarter and issued positive guidance for adjusted earnings per share.

Persons: Donald Trump, Robert F, Kennedy Jr, Eli Lilly, Warren Buffett, Berkshire Hathaway, Ulta, — CNBC's Sean Conlon, Alex Harring, Jesse Pound, Hakyung Kim, Lisa Han Organizations: Global pharma, Moderna, Pfizer, GSK, Novo Nordisk, Nasdaq, Securities and Exchange Commission, Super, New York Stock Exchange, Corp, Berkshire, Pool Corp, AST, Materials, LSEG Locations: China, Domino's, Berkshire

Shares of vaccine makers fell on Thursday as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, to lead the Department of Health and Human Services. Moderna’s stock closed more than 5% lower on Thursday, shares of Novavax fell more than 7% and Pfizer’s stock ended more than 2% lower. Shares of BioNTech, the German drugmaker that helped develop a Covid vaccine with Pfizer, closed more than 6% lower. Shares of those companies dipped further in extended trading as Trump confirmed his pick in a post on his platform Truth Social. Kennedy’s track record as a vaccine skeptic is extensive.

Persons: Donald Trump, Robert F, Kennedy Jr, Trump, Kennedy Organizations: Department of Health, Human Services, Pfizer, GSK, Health, Trump, Moderna, Health Defense Locations: Novavax, British, U.S

☆ Vaccine maker stocks tumble after Trump picks RFK Jr. for health secretary
▼ + stars: | 2024-11-14 | by ( Ramishah Maruf | ) edition.cnn.com time to read: +2 min

New York CNN —Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F. Kennedy Jr. to be the next secretary of the Department of Health and Human Services. An hour before the market closed Thursday, as news reports of Trump’s choice began trickling out, Covid-19 vaccine maker Moderna dipped as much as 6%, and Pfizer fell almost 2%. Novavax, which created a protein-based Covid-19 vaccine, fell almost 6%. Last week, Kennedy said he would “immediately” begin studying vaccine safety and efficacy but promised to not “take vaccines away from anybody.”Other vaccine-related companies also felt the fallout. Over the past year, Pfizer stock has dipped 11%, and Moderna stock has plunged 46%.

Persons: Donald Trump, Robert F, Kennedy Jr, Kennedy, “, Trump, ” Trump, CNN’s Kaitlan Collins, Kristen Holmes, Aaron Pellish Organizations: New, New York CNN, Department of Health, Human Services, Moderna, Pfizer, BioNTech, British GSK, Health, HHS Locations: New York, British

☆ Sundheim's D1 Capital adds new stakes in GE Healthcare, Bank of America
▼ + stars: | 2024-11-14 | by ( Jesse Pound | In Jesse-Pound | ) www.cnbc.com time to read: +1 min

Sundheim's D1 Capital added positions in GE Healthcare Technologies and Bank of America during the third quarter, a filing Thursday showed. Outside of those new positions and buying more shares of XPO Logistics , D1 Capital was mostly selling its top holdings. The hedge fund sold 22% of its biggest holding, Instacart , and 46% of its stake in cigarette maker Philip Morris . D1 Capital managed about $19 billion as of the end of last year. The extent of other holdings for D1 Capital is unclear.

Persons: Daniel Sundheim, Philip Morris Organizations: Sundheim's, GE Healthcare Technologies, Bank of America, XPO Logistics, D1, GE Vernova, Pfizer, Nu Holdings, Starbucks, Viking Global, D1 Capital Locations: Instacart

☆ Stocks making the biggest moves after hours: Domino's Pizza, Ulta, Applied Materials, Palantir and more
▼ + stars: | 2024-11-14 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Domino's Pizza , Ulta Beauty — Shares surged about 8% after Berkshire Hathaway announced a new stake in the pizza chain in a regulatory filling. The Warren Buffett-led firm bought more than 1.2 million shares, making the stake worth around $550 million at the end of September. Applied Materials — The semiconductor equipment manufacturer slid 5% after offering a weak revenue outlook for the current quarter. Applied Materials said to anticipate $7.15 billion in the first fiscal quarter, under the estimate of $7.224 billion from analysts polled by LSEG. Palantir will continue trading under the same ticker and expects to meet requirements to be listed in the Nasdaq 100 .

Persons: Berkshire Hathaway, Warren Buffett, Ulta, Despegar.com, FactSet, Robert F, Kennedy Jr, Donald Trump's Organizations: Berkshire, Materials, LSEG, Technologies, New York Stock Exchange, Nasdaq, Palantir, Department of Health, Human Services, Moderna, Pfizer Locations: Despegar.com —, Argentina

☆ Jim Cramer names hot sectors that could use a pullback
▼ + stars: | 2024-11-14 | by ( Julie Coleman | ) www.cnbc.com time to read: +2 min

CNBC's Jim Cramer on Thursday suggested the post-election market has been extreme, with big wins and big losses. "We have a lot of overly loved stocks in this market right now," he said. Cramer pointed out the sharp rise of enterprise software stocks, saying that it seems these companies with in-demand products for big corporations can do no wrong. Cramer also highlighted two sectors he said are "too hated," but could bounce back, including pharmaceuticals and semiconductors. For semiconductors, Cramer concluded that those companies have suffered in part because some feel that new artificial intelligence-powered PCs haven't taken off.

Persons: CNBC's Jim Cramer, Cramer, Salesforce, Donald Trump's, Trump, Robert F, Kennedy Jr Organizations: Costco, Netflix, Spotify, Merck, Pfizer, Human Services Department Locations: China

☆ Trump taps Robert F. Kennedy Jr. to lead Department of Health and Human Services
▼ + stars: | 2024-11-14 | by ( Alice Tecotzky | ) www.businessinsider.com time to read: +2 min

Trump has nominated Robert F. Kennedy Jr to lead the Department of Health and Human Services. The president-elect previously vowed to let Kennedy "go wild on health." AdvertisementTrump has nominated former presidential candidate Robert F. Kennedy Jr. to lead the Department of Health and Human Services, likely sparking a confirmation battle in the Senate. "I am thrilled to announce Robert F. Kennedy Jr. as The United States Secretary of Health and Human Services (HHS)," Trump wrote on Truth Social. Representatives for Trump and Kennedy did not immediately respond to a request for comment.

Persons: Trump, Robert F, Kennedy Jr, Kennedy, —, Obama, Semafor Organizations: Department of Health, Human Services, Service, United, Health, Public Health, Biden, and Drug Administration, Pfizer, Moderna, Trump, HHS

Whereas cases of the STI in newborns increased by 30% annually in recent years — greatly alarming public health experts — the upward trend has decelerated. San Francisco’s Public Health Department was the first to recommend doxyPEP for gay and bisexual men and trans women, in October 2022. That helped trigger a long decline in condom use among gay and bisexual men in particular. The protocol, called doxyPrEP, demonstrated generally comparable efficacy at preventing STIs compared with doxyPEP studies among gay men. Public health experts have attributed this century’s surge in STIs, at least in part, to a steady defunding of state and local public-health clinics.

Persons: STIs, gonorrhea, Chlamydia, ”, Laura Bachmann, Julie Dombrowski, Pfizer’s, doxyPEP, MISTR, Jeffrey Klausner, Trump, ” Klausner, “ Organizations: Centers for Disease Control, Blacks, NBC News, MediaNews, Getty, University of Washington, Public Health Department, CDC, PrEP, Food and Drug Administration, HIV, University of Southern Locations: Seattle, gonorrhea, Chicago, New York, Africa, Puerto Rico, ”, Munich, Canada, Japan, University of Southern California

☆ These 2 stocks beat the S&P 500 in election Novembers no matter who won
▼ + stars: | 2024-11-06 | by ( Ganesh Rao | ) www.cnbc.com time to read: +3 min

Two stocks have outperformed the S & P 500 every November when elections have been held over the past three decades — regardless of the outcome, according to a CNBC Pro study. Electrical and industrials giant Eaton Corporation and Sweden's second-largest lender, Svenska Handelsbanken , are the two stocks that beat the U.S. benchmark in November every election year. CNBC Pro screened for stocks currently in the MSCI World Index that gained more than the S & P 500 — or lost less than the index — in November of every election year since 1988. Every time is different Historical performance is never a guarantee of future performance, and stocks often move for idiosyncratic reasons. This year, for instance, the Federal Reserve is expected to announce a decision on interest rates on Thursday, which could also influence the trajectory of stocks.

Persons: Brett Linzey, Mizuho, Eaton, Arctic's Roy Tilley, Henry Allen, Pfizer's, Barack Obama, Allen Organizations: CNBC, Eaton Corporation, Svenska, CNBC Pro, Eaton Corp, Mizuho, Svenska Handelsbanken, Arctic Securities, Federal Reserve, Deutsche Locations: U.S, Industrials, Sweden, Greece, Europe

☆ Trump says he will give RFK Jr. a major health role if he wins the White House. Here's what that means for patients, drugmakers
▼ + stars: | 2024-11-05 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +10 min

Some health experts said elevating Kennedy, even in an informal Trump administration position, could potentially lead to severe consequences for patients, drugmakers and the nation's public health overall. That could exacerbate the nation's existing public health challenges, such as declining childhood vaccination rates for several preventable diseases, some experts say. "I think we could reasonably predict that there would be a decline in vaccination rates among children, and perhaps vaccination overall." Drugmakers such as Pfizer and Moderna are still recovering from falling Covid vaccination rates in the U.S., which have dented their profits over the last two years. Kennedy's other proposals for overhauling federal health agencies will likely be difficult to execute.

Persons: Donald Trump, Robert F, Kennedy Jr, Anna Moneymaker, Kennedy, Trump, Dr, Paul Offit, Drew Altman, Altman, Genevieve Kanter, Cynthia Blancas, Deep Patel, Christina House, they've, Offit, Andrew Kelly, USC's Kanter, that's, Georges Benjamin, Covid, Kanter Organizations: Gas, Getty, White House, Trump, Children's Hospital of Philadelphia, CNBC, and Drug Administration, Centers for Disease Control, Commonwealth Fund, Senate, Washington Post, University of Southern, CVS, Los Angeles Times, CDC, Pfizer, Moderna, NBC, Health Defense, FDA, Department of Health, Human Services, U.S . Food, Drug Administration, Reuters, American Public Health Association, Pharma Locations: Duluth , Georgia, U.S, University of Southern California, Lynwood, Huntington Park, Samoa, White Oak , Maryland

In October, the Centers for Disease Control and Prevention recommended that high-risk adults get a second updated Covid vaccine to bolster their protection against the virus. No other vaccines are given at such a high frequency, but experts say there’s no reason to believe that the vaccines — and in particular, the mRNA vaccines from Pfizer and Moderna — aren’t effective. Pfizer’s and Moderna’s vaccines were the first to use mRNA technology to induce immunity to a virus, an approach that proved critical in the early days of the pandemic because mRNA vaccines can be developed much faster than traditional vaccines. Despite the CDC recommending an additional shot, there’s no evidence that the mRNA vaccines aren’t working as expected, said Akiko Iwasaki, a professor of immunology at the Yale School of Medicine. In a perfect world, the Covid vaccines would be able to be updated much faster to match the strains in circulation.

Persons: Akiko Iwasaki, Iwasaki, —, ”, Ashish Jha, ” Jha, “, Jha, I’ve, “ Topping, John Wherry, ” Wherry, Anna Durbin, ” Durkin, we’ll Organizations: Centers for Disease Control, Pfizer, Moderna, CDC, Yale School of Medicine, Emory University, Brown University School of Public Health, White, University of Pennsylvania, Johns Hopkins University School of Medicine

☆ Final Trades: Dell, Leidos Holdings, Pfizer and Trade Desk
▼ + stars: | 2024-10-30 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailFinal Trades: Dell, Leidos Holdings, Pfizer and Trade DeskThe Investment Committee give you their top stocks to watch for the second half.

Organizations: Dell, Leidos Holdings, Pfizer, Trade

☆ Eli Lilly's quarter was messy. What to do with the stock is more clear-cut
▼ + stars: | 2024-10-30 | by ( Kevin Stankiewicz | ) www.cnbc.com time to read: +11 min

The report was messy, but it doesn't dim Eli Lilly's bright multiyear outlook, rendering the dip in the stock as a chance to buy. LLY .SPX 5Y mountain Eli Lilly's five-year stock performance compared with the S & P 500. Bottom line We're upgrading Eli Lilly to our buy-equivalent 1 rating and leaving our price target of $1,000 a share unchanged. Eli Lilly Why we own it: Eli Lilly's best-in-class drugs should enable growth above the industry average for many years to come. Eli Lilly's new Alzheimer's drug Kisunla, which was approved by the FDA in July, was not a major focus on the call.

Persons: Eli Lilly, Eli, Eli Lilly's, Jim Cramer, Jim, —, that's, David Ricks, Ricks, Semaglutide, Wegovy, Lilly, There's, Mounjaro, Trulicity, Verzenio, Jim Cramer's, Cristina Arias Organizations: Revenue, The Club, CNBC, JPMorgan, Novo Nordisk, Food, Novo Nordisk's, FDA, Zepbound, Biogen, Merck, Pfizer, Morphic, Company, Pharmaceutical Locations: Tuesday's, U.S, Novo, Eisai, FactSet, Zepbound, Alcobendas, Madrid, Spain

☆ 3-Stock Lunch: Chipotle, Pfizer & Ford
▼ + stars: | 2024-10-29 | by ( ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via Email3-Stock Lunch: Chipotle, Pfizer & FordMAI Capital’s Chris Grisanti, joins 'Power Lunch' to discuss stock plays for three stocks.

Persons: Chris Grisanti Organizations: Pfizer, Ford MAI

☆ Pfizer CEO says he welcomes good ideas as Starboard ups pressure on company
▼ + stars: | 2024-10-29 | by ( Julie Coleman | ) www.cnbc.com time to read: +1 min

In a Tuesday interview with CNBC's Jim Cramer, Pfizer CEO Albert Bourla struck a positive tone about activist investor Starboard Value, saying he agreed with some of its criticisms, but maintained that the company is headed in a good direction. But if Starboard, and anybody else for that matter, have good ideas, I will certainly discuss them and entertain." The pharmaceutical giant is under pressure from Starboard, which reportedly has a $1 billion stake in the company. But he praised Starboard's CEO Jeff Smith, saying he seemed "very smart" and "very pragmatic" at a recent meeting. Bourla also rebuked claims that his company was involved in dissuading past executives — former CEO Ian Read and former CFO Frank D'Amelio — from joining Starboard's efforts.

Persons: CNBC's Jim Cramer, Albert Bourla, Bourla, Jeff Smith, Ian Read, Frank D'Amelio — Organizations: Pfizer

☆ Pfizer CEO Albert Bourla goes one-on-one with Jim Cramer
▼ + stars: | 2024-10-29 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO Albert Bourla goes one-on-one with Jim CramerPfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, and more.

Persons: Albert Bourla, Jim Cramer Pfizer, Jim Cramer Organizations: Pfizer

☆ Pfizer CEO Albert Bourla talks working with Starboard
▼ + stars: | 2024-10-29 | by ( Jim Cramer | ) www.cnbc.com time to read: 1 min

In this videoShare Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailPfizer CEO Albert Bourla talks working with StarboardPfizer Chairman and CEO Albert Bourla joins 'Mad Money' host Jim Cramer to talk quarterly results, what's in the pipeline, and more.

Persons: Albert Bourla, Jim Cramer Organizations: Pfizer

☆ This is Cramer's favorite stock even though it's down 10% since earnings last week
▼ + stars: | 2024-10-29 | by ( Paulina Likos | ) www.cnbc.com time to read: +2 min

Every weekday the CNBC Investing Club with Jim Cramer holds a "Morning Meeting" livestream at 10:20 a.m. Shares of Stanley Black & Decker were pairing some of their post-earnings losses since the Morning Meeting was recorded — down about 9% now. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Stocks, Larry Fink, bode, Stanley Black, Decker, Jim, Danaher, Horton, Jim Cramer's Organizations: CNBC, Big Tech, Club, BlackRock, Home, VF Corp, Pfizer, AMD Locations: Riyadh, Saudi Arabia

☆ Stocks making the biggest moves premarket: VF Corp, McDonald's, Pfizer, PayPal and more
▼ + stars: | 2024-10-29 | by ( Sean Conlon | ) www.cnbc.com time to read: +6 min

For the fiscal second quarter, the company posted adjusted earnings of 60 cents per share on $2.76 billion in revenue. Cadence Design Systems – The stock jumped more than 5% after the electronic design company's third-quarter earnings beat Wall Street estimates. JetBlue's third quarter results did beat analyst estimates on the top and bottom lines. PayPal – Shares fell 3% after PayPal posted third-quarter revenue that missed expectations. Crocs – Shares tumbled around 12% despite the company's third-quarter earnings beating estimates.

Persons: Ford, Trex, FactSet, Jim Conroy, John Hazen, Conroy, Crypto, Stocks, Horton, PayPal –, StreetAccount, Crocs, Lisa Kailai Han, Samantha Subin, Jesse Pound, Sarah Min, Pia Singh, Tanaya Macheel, Michelle Fox Theobald Organizations: Corporation, Ford Motors, Cadence, Systems, BP –, Pfizer, Revenue, Ross Stores, JetBlue –, JetBlue, LSEG, Mizuho, PayPal, FactSet, Xerox

☆ Stocks making the biggest moves midday: VF Corporation, Pfizer, F5, JetBlue and more
▼ + stars: | 2024-10-29 | by ( Brian Evans | ) www.cnbc.com time to read: +5 min

Check out the companies making headlines in midday trading: VF Corporation — Shares jumped more than 22%. VF Corporation posted adjusted earnings of 60 cents per share on revenue of $2.76 billion. That is above the 37 cents per share in earnings and $2.71 billion in revenue that analysts surveyed by LSEG were expecting. The firm also upped the midpoint of its non-GAAP earnings per share forecast for the full year. F5 posted adjusted earnings of $3.67 per share and revenue of $747 million in the fiscal fourth quarter.

Persons: LSEG, Jim Conroy, Trex, FactSet, Xerox, Horton, Corning, — CNBC's Pia Singh, Michelle Fox, Samantha Subin, Sean Conlon, Alex Harring Organizations: —, Cadence, BP — U.S, BP, Pfizer, JetBlue Airways —, JetBlue, LSEG, Xerox, FactSet, PayPal, Caribbean, Ford Locations: Corning

☆ Pfizer tops earnings estimates, hikes full-year guidance as Covid products help sales
▼ + stars: | 2024-10-29 | by ( Annika Kim Constantino | ) www.cnbc.com time to read: +4 min

Pfizer on Tuesday reported third-quarter revenue and adjusted profit that blew past expectations as the company's Covid vaccine and antiviral pill Paxlovid helped boost sales. Pfizer now expects revenue in a range of $61 billion to $64 billion, up from a previous revenue forecast of between $59.5 billion to $62.5 billion. That includes roughly $5 billion in expected revenue from its Covid vaccine and $5.5 billion from Paxlovid. Pfizer reported revenue of $17.7 billion for the third quarter, up 31% from the same period a year ago. Notably during the quarter, Pfizer withdrew from world markets a critical sickle cell drug it had acquired in a $5.4 billion deal for Global Blood Therapeutics.

Persons: Jeff Smith, Smith, Paxlovid, StreetAccount, Covid Organizations: Pfizer, LSEG, Global Blood Therapeutics Locations: U.S

☆ Stock futures are little changed as Wall Street awaits labor data and more earnings: Live updates
▼ + stars: | 2024-10-28 | by ( Alex Harring | ) www.cnbc.com time to read: +2 min

Traders work on the floor of the New York Stock Exchange during morning trading in New York City. Stock futures are muted Monday night as investors readied for employment data and closely followed corporate earnings releases. S&P 500 futures and Nasdaq 100 futures were also both little changed. Those moves come after a winning session on Wall Street for the three major indexes. Traders will keep an eye on earnings reports from major companies due on Tuesday as the busiest week of this earnings season continues.

Persons: Dow, Adam Crisafulli, McDonald's Organizations: New York Stock Exchange, Stock, Dow Jones Industrial, Nasdaq, Ford Motor, Corp, Traders, Pfizer Locations: New York City, Israel, Iran

☆ Oil sell-off fuels stock gains — plus, AMD earnings loom and CrowdStrike counters Delta lawsuit
▼ + stars: | 2024-10-28 | by ( Jeff Marks | ) www.cnbc.com time to read: +5 min

Every weekday, the CNBC Investing Club with Jim Cramer releases the Homestretch — an actionable afternoon update, just in time for the last hour of trading on Wall Street. We would be surprised if CEO Lisa Su provided 2025 AI chip sales guidance. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade. THE ABOVE INVESTING CLUB INFORMATION IS SUBJECT TO OUR TERMS AND CONDITIONS AND PRIVACY POLICY , TOGETHER WITH OUR DISCLAIMER . NO FIDUCIARY OBLIGATION OR DUTY EXISTS, OR IS CREATED, BY VIRTUE OF YOUR RECEIPT OF ANY INFORMATION PROVIDED IN CONNECTION WITH THE INVESTING CLUB.

Persons: Jim Cramer, Lisa Su, Raymond James, George Kurtz, Delta, Stanley Black, Decker, Hubbell, Jim Cramer's, Jim Organizations: CNBC, ., West Texas, AMD, Intel, Air Lines, Microsoft, Atlanta, Ford Motor, Cadence Design Systems, Corp, PayPal, Pfizer, Royal Caribbean Cruises, Jim Cramer's Charitable Locations: Israel, Corning

Search resuls for: "Pfizer"

25 mentions found